Psycho emotional state of coronary heart disease (CHD) patients and its influence on CHD treatment outcome has been studied according to CES-D and НАDS(D) questionnaires. It was demonstrated that the use of agomelatine leads to the decrease of anxiety and depression evidence.
Introduction
Cardiovascular disease is the first reason in the list of overall mortality of Russian population. Cardiovascular disease is the reason of the death of 1,3 million of Russians which is about 56% of the number of registered deaths. High spread and juvenation of CHD is strongly connected with the increase of psycho-emotional trouble in society. Periods of socio-economical crisis are accompanied with emotional stress and depressive disorders, and consequently, reduce of the life time, increase of the fatality and sickness rates.
The recent researches give the evidence that depression becomes an independent risk factor of arterial hypertension (AH) and CHD, as well as more serious epiphenomenon such as acute myocardial infarction (MI) and cerebral stroke. Depression complicates clinical progression, treatment and secondary prevention, it also worsen the life quality of patients. The risk of CHD is higher among those who are suffering from depression, and vise versa depression is more often diagnosed at CHD patients (Bromet, 2011 , Kopina, 1996 , Barefoot, 1996 , Wulsin, 1999 , Anda, 1993 . The degree of depression incidence can reach up to 20% among CHD patients, and it can be up to 30% among patients underwent MI (Pogosova, 2002) . The risk of rehospitalization and fatal outcome is higher in case of the CHD and depression combination regardless of which of these sicknesses appeared first.
One of the perspective instruments of the pharmacological correction of the depression, which is actually a new approach to its treatment, is the first melatonergic antidepressant agomelatine "Valdoxan" produced by the French pharmaceutical company Servier. This is the medicinal remedy with innovational characteristics. The unique profile of the receptor binding of agomelatine explains its strong antidepressant effect and complementary clinical attribute. The medical remedy normalizes circadian rhythms, restore a good sleep, it is neutral towards the body mass, and it hasn't negative effect towards the genital sphere. Complying antidepressive impact of the medicament, these qualities help to improve compliance and increase therapeutic effect of agomelatine.
Psycho emotional state of the CHD patients and the influence of melatonergic antidepressant agomelatine (Valdoxan) on it were studied during the research.
The research was organized in two stages, as follows: firstly, piloting stage was dedicated to the evaluation of the psycho emotional state of patients who were hospitalized to the acute cardiology unit of the Kazan Emergency care hospital #1; the first group was presented with patients hospitalized to the reanimation and intensive care ward with 20 people (7 men and 13 women at the age of 43-79 years, in average 64,33±1,57 years). There were 13 people with acute myocardial infarction, 4 with effort angia of III-IV function classes, 2 with atrial fibrillation. At the second stage the influence of Valdoxan on the clinical and subclinical depression and axiety progress was studied at 38 CHD patients at the age of 43-79 years (10 men and 28 women, average age is 66,44±3,39 years). There were 27 patients with acute myocardial infarction (among them 8 with repeated), 9 with effort angia of III-IV function classes, 9 with atrial fibrillation; 21 patients of this group suffered from hypertensive disease, and 3 had symptoms of cardiac asthma. It bears mentioning, that 4 patients were brought to the hospital with cardiogenic shock of the I-II degree, and 4 -with pulmonary edema. Conduction defects with block of the left or right His bundle branch were diagnosed at 4 patients, and rhythm disturbance in pair multifocal multiform infranodal and auricular extrasystoles were diagnosed at 2 patients. Aiming to correct depression and anxiety order these patients were ordered to take antidepressant agomelatine (Valdoxan) -melatonin agonist (MT 1 -and MT 2 -receptors) and 5HT 2c -receptors agonist in a dose of 25 mg every evening.
All patients were surveyed according to the CES-D depression scale and НАDS (D, T) scale in terms of determination of their psycho emotional state at the 2 nd , 6 th and 14 th day at the hospital. The outcome was interpreted as follows: remarkable depression or anxiety ->25 points according to the CES-D scale and 11 points according to the НАDS (D, T) scale; subclinical remarkable anxiety/depression -19-25 or 8-10 points; the absence of definitively remarkable symptoms of anxiety/depression 0-19 or 0-7 points.
Statistic material handling was organized with the use of standard program package Statistica.
Regarding the first group (n=20) of patients who were at the reanimation and intensive care ward, 15 (75%) of patients were diagnosed with depression at the second day. Among them 5(25%) patients were diagnosed with remarkable depression according to the CES-D scale, 10 (50%) with light, and 5(25%) -without pathological findings. There were 19 (95%) of patients who were diagnosed with depression according to the НАDS(D) scale, among them 15(75%) -clinically apparent, 4(20%) -subclinical and 1(5%) -wasn't diagnosed with depression. Expressed depression according to the CES-D scale remained at 1(5%) patient and at 7(35%) -light depression at the 14 th day. Clinically apparent depression remained at 6(30%) patients and subclinical at 7(35%) according to the HADS(D) scale.
Regarding the second group (n=20) of patients, 6 (30%) of patients were diagnosed with depression at the second day according to the CES-D scale, and among them 2 (10%) patients were diagnosed with remarkable depression, 4 (20%) -light depression; 14(70%) didn't have psychiatric disorder. However, according to the HADS(D) scale 16 (80%) patients were diagnosed with depression, among them 7(35%) -clinically apparent, 9(45%) -subclinical, and 4(20%) -no depression. There were only 3(15%) patients with light depression according to the CES-D scale; and 3(15%) -clinically apparent, 4(20%) subclinical according to the HADS(D) scale on the 14 th day.
Summarized data about the depression levels according to the CES-D scale at the 2 nd and 14 th days is presented at the Figures 1, 2 . According to the HADS(D) scale, depression was diagnosed at 35(87,5%) patients, among them: 22(55%) -remarkable depression, 13 (32,5%) -subclinical, and 5 (12,5%) -no depression; at the 14 th day there were 9(25,7%) of 35 patients with clinically apparent depression, and 11 (31,43%) with subclinical. The level of the depression according to the CES-D scale of 38 patients taking Valdoxan at the second day is presented at the Figure 3 . According to the HADS(D) scale anxiety at the 2 nd day was revealed at 29 patients, among them 16(42,1%) -subclinical depression, and 13 (34,2%) -clinically apparent depression, 9 (23,7%) -without pathology. At that time, there were 19 (50%) of depressed people, among them 12 (31,6%) -subclinical depression, 7 (18,45%) -clinically apparent depression, and 19 (50%) -without significant depression. There were 5 (13,15%) people with light depression and 13 (34,2%) with remarkable depression at the 6 th day according to the CES-D scale. According to the HADS(D) scale, there were 6 (15,8%) patients with clinically apparent depression and 4 (10,5%) -with light depression. According to the HADS(D) scale, anxiety disorder was noted at 11 people, among them 6 (15,7%) -in subclinical form, and 5 (13,1%) -in clinically apparent form. At the time of hospital discharge (10 th -14 th day), there were only 3 patients with light depression(initially 38 patients had clinically apparent depression); their anxiety level has reduced (Figure 4 ), so they were proposed to continue outpatient use of Valdoxan.
Subjective feelings, as mood, sleep, psycho-emotional state, improved already on the 2-4 th days of the medication use. Above that, Valdoxan demonstrated metabolical neutrality, which extends the opportunities of its use for the different groups of patients. Functional tests which were organized during 14 days of attendance haven't significantly changed, alanine/aspartate transaminase content was in average 38,08±1,34/28,6±2,32 и 39,26±1,65/30,1±2,53 u/l at the 2 nd and 14 th days accordingly. Myocardial infarct, absolute data (%)
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3 (15) 14 (70) 17 ( Among the patients hospitalized to the acute cardiology unit more that ½ (52,5-82,5% according to the evaluation methods) suffer from anxiety/depression disorder, it is worth mentioning that psycho-emotional disorder can be found more often at women over 60 years with more serious cardio-vascular anamnesis, as follows: the first or repeated acute myocardial infarct, with arterial hypertension of II-III degree. It is notable that social state also has a significant effect, so people underwent spouse lost (widows) are more liable to significant anxiety/depressive disorders.
It bears mentioning that being in reanimation and intensive care ward correlates with worse psycho emotional state of CHD sickness. High anxiety or depression level at these patients can become the reason of the secondary disorder connected to the severity of illness and/or condition, to the fact of the serious diagnosis was established, or to being in reanimation and intensive care ward. So, the level of the depression at significant majority of patients has significantly reduced after shifting to the general medical unit.
Anxiety-depressive disorder at the CHD patients regress together with the main treatment, so it is as follows: from 52,5 to 27,5% (CES scale) and from 82,5 to 58% (HADS scale) at the 6 th day in the hospital. It may be due to reduce of the symptoms marks and the enlargement of physical activity. The use of Valdoxan optimize the psycho emotional state of the ptients, so the frequency of anxiety disorders to the 14 th day of the treatment reduced from 76,9 to 2,63%, depressions -from 50 to 7,89% (and all the remained cases are of light depression).
The including of new antidepressant Valdoxan to the complex therapy of CHD patients suffering from depression in the dose of 25 mg per day can significantly improve the life quality of patients, which is finally effects the stabilization of the main sickness and improves the life perspectives. Metabolical neutrality of the medicament let recommend it to the patients of different groups, and 1 pill for the night encourage high medication adherence.
To sum up, taking into account possible worsen of the progress and perspective of CHD together with psycho emotional state disorder, we recommend to survey cardiology patients according to CES-D and HADS(D) methodology and in case of anxiety or depression treat them with the use of Valdoxan.
